Latest News for Cannabis Bioscience Stock (OTC:CBIH)

Cannabis Bioscience International Holdings Inc is engaged in providing educational systems relating to cannabis and services in therapeutic areas. of clinical trials and services relating to sleep disorders through its sleep center in Houston, Texas. The Company generates revenue from multiple streams, namely, clinical trials, consulting fees, video courses, seminars, royalties, and merchandise sales. The company generates the majority of its revenue from clinical trials.

hunters-race-MYbhN8KaaEc-unsplash(9)

Cannabis

News

Movers

BLOZF

CBIH

CMPS

CSE:BLO

CSE:GWAY

CSE:IAN

CSE:JSDA

CSE:JUSH

DBCCF

GWAYF

ITHUF

JSDA

JUSHI HLDGS INC CL B by Jushi Holdings Inc.

JUSHF

SHWZ

TSXV:DB

TSXV:HASH

Who&#39;s Who In Cannabis: Latest Executive Changes You Should Know About

louis-reed-pwcKF7L4-no-unsplash(2)

Offerings

Cannabis Bioscience, a Houston-based clinical research company, has announced plans to conduct cannabis clinical trials using artificial intelligence (AI) programs. The company aims to optimize the research processes and promote the use of cannabinoid therapies as a first option for patients. Proceeds from a stock offering by selling shareholders will be used to fund these trials.

SEC Green Lights Public Listing Of Texas Cannabis Co. That Will Use AI In Clinical Trials

CANNABIS BIOSCI INTL HLDG by CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.

Cannabis Bioscience International Holdings Inc

With an integrated tech stack built in just five months, L'azurde has seen its conversion rates double alongside significant improvements in sales growth, uptime and site stability
<a href="https://www.bigcommerce.co.uk/solutions/fashion/?utm_medium=pr&amp;utm_source=businesswire&amp;utm_campaign=com_global_all_mme_acq-cus_verti-fashion_brand_ct_2024_q2_lazurde-press-release&amp;utm_content=luxury-jewelry-brand-l%E2%80%99azurde-launches-elegant-new-composable-commerce-website-on-bigcommerce">BigCommerce</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIGC#NASDAQ">BIGC</a>), an open SaaS, composable ecommerce platform for fast-growing and established B2C and B2B brand and retailers, today announced that <a href="https://www.lazurde.com/en-sa">L'azurde Company for Jewelry</a>, one of the Middle East's largest jewelry designers, manufacturers and distributors, has launched on the BigCommerce platform.

BIGC

L'azurde Launches Elegant New Composable Commerce Website On BigCommerce

Management

KRON

Kronos Bio Appoints Deborah Knobelman As COO And CFO, EFfective Jun. 3

Topline data now projected in early Q4 2024 &nbsp;
Rohit Loomba, MD, MHSc to serve as Principal Investigator
SOUTH SAN FRANCISCO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGS#NASDAQ">ALGS</a>, "Aligos")))), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it has completed enrollment in the ALG-055009 Phase 2a HERALD study for metabolic dysfunction-associated steatohepatitis (MASH) with topline safety and efficacy data anticipated in early Q4 2024. The company also announced that Dr. Rohit Loomba will serve as Principal Investigator for the study.

Biotech

General

ALGS

Aligos Therapeutics Completes Enrollment In The ALG-055009 Phase 2a HERALD Study For The Treatment Of MASH

Solera and Axalta partner together to accurately calculate CO2 emissions per vehicle repair.
Solera, the global leader in vehicle lifecycle management, today announced a strategic partnership with Axalta (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXTA#NYSE">AXTA</a>), a leading global supplier of liquid and powder coatings. Through this strategic partnership, Axalta's conventional and Fast Cure Low Energy (FCLE) refinish paint systems will be integrated into Solera's Sustainable Estimatics platform, enabling Axalta Customers to analyze their CO2 emissions per repair, considering repair methods (repair versus replace), paint application process, and drying conditions.

AXTA

Solera, Axalta Partner Together To Accurately Calculate CO2 Emissions Per Vehicle Repair.

BLNK

Blink Charging Selected By BYD Dealership Group, Grupo Fame, To Provide EV Charging Services At Select Locations

Telsey Advisory Group analyst Joseph Feldman maintains Lowe's Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) with a Market Perform and maintains $230 price target.

Price Target

Analyst Ratings

Telsey Advisory Group Maintains Market Perform on Lowe's Companies, Maintains $230 Price Target

Apple Inc. co-founder <a href="https://www.benzinga.com/topic/steve-jobs">Steve Jobs</a> revolutionized multiple industries during his life, but Walter Isaacson, the biographer of both Jobs' and <a href="https://www.benzinga.com/topic/elon-musk">Elon Musk</a>, thinks that the Tesla Inc. CEO is in a "league of his own."
What Happened: In a conversation with Lex Fridman, Isaacson dived into Musk's thought process and how he manages time between his personal life, and his professional life where he manages Tesla, SpaceX, and X, formerly Twitter, among others.
Isaacson, who has had a close peek into the lives of both the tech titans, thinks "Musk is in a league of his own in the way he does it" as far as time management is concerned.
"First of all, Steve Jobs had to run Pixar and Apple for a while, but Musk every couple of hours is switching his mindset from how to implant the Neuralink chip and what will the robot that implants it in the brain look like and how fast can we make it move?"
See Also: <a href="https://www.benzinga.com/news/24/05/38929147/5-money-mistakes-billionaire-elon-musk-made">5 Money Mistakes Billionaire Elon Musk Made</a>
Isaacson recalled an incident where Musk went to the SpaceX Starbase in Boca Chica, Texas, to think about how to fix a valve in the Raptor engine with a methane leak issue.
"All the engineers in that room, I assume, or thinking about, ‘This guy just bought Twitter, should we say something?'"
Isaacson says Musk then went to a roadside joint in Brownsville with his brother Kimbal Musk to do nothing but listen to the music.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
<h2 class="wp-block-heading">Musk's Strength, As Well As Weakness, Is This</h2>
Isaacson marveled at Musk's ability to multitask, saying this is one of his strengths as well as weaknesses.
"One of his strengths and sort of weaknesses in a way is in a given day, he'll focus serially, sequentially, on many different things."
"He's a serial tasker, which means focuses intensely on a task for an hour," Isaacson added, and Musk now has a comeback – he says he switches context every five minutes now, and sometimes in just 30 seconds.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Actually, I'm switching context roughly every 5 mins on average and sometimes every 30 secs if going through texts/email. A full hour on a single subject would be a long time.
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1790123218201682199?ref_src=twsrc%5Etfw">May 13, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Walter Isaacson: Elon Musk, Steve Jobs, Einstein, Da Vinci &amp; Ben Franklin &#x7C; Lex Fridman Podcast #395" width="500" height="281" src="https://www.youtube.com/embed/aGOV5R7M1Js?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Check out more of&nbsp;Benzinga's&nbsp;Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next: <a href="https://www.benzinga.com/news/24/05/38912528/forget-musk-vs-zuckerberg-fight-tesla-ceo-recalls-duel-with-sumo-wrestler-that-gave-him-few-minutes">Forget Musk Vs. Zuckerberg Fight, Tesla CEO Recalls Duel With Sumo Wrestler That Gave Him &#8216;Few Minutes Of Glory&#8217; And &#8216;8 Years Of Neck Pain&#8217;</a>
Photos courtesy: Shutterstock and Wikimedia

Tech

Elon Musk Is In A 'League Of His Own,' Says Steve Jobs And Tesla CEO's Biographer: 'He's A Serial Tasker'

-Reuters, citing presentation&nbsp;

Guidance

Macy's Expects Q2 Adj EPS Between $0.25-$0.33 vs $0.22 Est., Net Sales $4.97B-$5.1B vs $5.08B Est.

Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) reported quarterly losses of $(2.00) per share which missed the analyst consensus estimate of $(1.04) by 92.31 percent. This is a 75 percent increase over losses of $(8.00) per share from the same period last year. The company reported quarterly sales of $7.54 million which beat the analyst consensus estimate of $7.00 million by 7.73 percent. This is a 54.08 percent increase over sales of $4.89 million the same period last year.

Earnings

SBFM

Sunshine Biopharma Q1 EPS $(2.00) Misses $(1.04) Estimate, Sales $7.54M Beat $7.00M Estimate

TD Cowen analyst John Kernan maintains Dick's Sporting Goods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) with a Buy and lowers the price target from $226 to $224.

TD Cowen Maintains Buy on Dick's Sporting Goods, Lowers Price Target to $224

Larian Studios, known for hit games Divinity: Original Sin 2 and Baldur's Gate 3, is opening its seventh studio in <a href="https://www.benzinga.com/general/gaming/24/02/37136304/whats-behind-hasbros-90m-boost-this-game-with-full-nudity-and-romance-with-a-bear-could-hold-the-a">Warsaw, Poland. </a>
This expansion is part of the company&#8217;s ongoing efforts to develop at least two new, &#8220;very ambitious&#8221; RPGs, as the company noted on X (formerly Twitter)
See Also: <a href="https://www.benzinga.com/general/gaming/24/03/37882963/sad-news-for-baldurs-gate-3-fans-larian-studios-ends-downloadable-content-sequel-plans-moves-beyon">Sad News For Baldur&#8217;s Gate 3 Fans: Larian Studios Ends Downloadable Content, Sequel Plans; Moves Beyond &#8216;Dungeons &amp; Dragons&#8217;</a>
Founded 28 years ago by Swen Vincke, Larian has grown into a global presence with studios in Ghent, Kuala Lumpur, Quebec City, Dublin, Guildford, Barcelona, and now Warsaw.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&#x2A;obtains condition Enlarged&#x2A; With two very ambitious RPGs now starting development, what better way to see our visions realised than by growing the team and opening a 7th studio in the heart of Poland's lively gaming scene! Welcome, Larian Studios Warsaw! <a href="https://t.co/hpm2aMdQmy">pic.twitter.com/hpm2aMdQmy</a>
&mdash; Larian Studios (@larianstudios) <a href="https://twitter.com/larianstudios/status/1792495491256664211?ref_src=twsrc%5Etfw">May 20, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Larian&#8217;s journey has been remarkable, transforming from a company known for its average early games in the Divine Divinity series to one that shocked the gaming world with the critically acclaimed Divinity: Original Sin in 2014. 
This success was built on a modest budget of €4 million, followed by its 2017 sequel, which raised $2 million via Kickstarter and underwent an extended Early Access period, setting the stage for the monumental success of Baldur's Gate 3.
Baldur&#8217;s Gate 3, with a reported budget of $100 million, significantly exceeded expectations, grossing over $650 million in 2023. This financial success underscores Larian's evolution into a major independent game developer, capable of significant investment and risk-taking without the pressure from publishers or shareholders.
Currently, Larian is actively recruiting developers for the new Warsaw studio, potentially tapping into the local talent pool, including developers from CD Projekt Red, known for their expertise in RPGs. 
Read Next: <a href="https://www.benzinga.com/general/gaming/24/03/37895431/a-really-stupid-deal-larian-studios-reflects-on-googles-stadia-misstep-team-joyous-over-no-more-ba">&#8216;A Really Stupid Deal&#8217;: Larian Studios Reflects On Google&#8217;s Stadia Misstep, Team Joyous Over No More Baldur&#8217;s Gate 3</a>
Photo: Shutterstock

Gaming

Larian Studios, Creator Of Baldur's Gate 3, Launches Seventh Studio For 'Very Ambitious' RPGs

Nano Labs Launches New Product Cuckoo3.0 Chip With Significant Improvements In Performance And Energy Efficiency

Chardan Capital analyst Keay Nakae maintains Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) with a Buy and raises the price target from $31 to $42.

Chardan Capital Maintains Buy on Dyne Therapeutics, Raises Price Target to $42

Nano Labs Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NA#NASDAQ">NA</a>) ("we," the "Company" or "Nano Labs"), a leading fabless integrated circuit design company and product solution provider in&nbsp;China, today announced that it has launched its latest generation in the Cuckoo series, Cuckoo3.0 chip and achieved the mass production. Cuckoo3.0 represents a significant leap in performance and energy efficiency compared to its predecessor, the Cuckoo2.0 chip.
&nbsp;
With an outstanding single-core computing power of 1.2GH/s, Cuckoo3.0 boasts approximately four times the functional performance of Cuckoo2.0. Additionally, its single-core energy consumption has been drastically reduced to 0.14W/MHash, marking an 83% improvement in energy efficiency. Cuckoo3.0 is expected to be integrated into the Company's next-generation V series products, reinforcing the Company's commitment to pushing the boundaries of technology in the Web3.0 industry.

Nano Labs Launches Cuckoo3.0 Chip With Improvements In Performance And Energy Efficiency

Visa Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>),&nbsp;Mastercard Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>), and their increasing fees on retailers have not resulted in significant service improvements,&nbsp;<a target="_blank" href="https://www.psr.org.uk/news-and-updates/latest-news/news/psr-provisionally-finds-that-the-cards-schemes-do-not-face-effective-competition-in-the-supply-of-scheme-and-processing-services-to-acquirers/" rel="noreferrer noopener">according&nbsp;</a>to the provisional findings of&nbsp;Britain&#8217;s&nbsp;Payment Systems Regulator (PSR).
The PSR expressed concerns that&nbsp;competition within the market is lacking, leading to these&nbsp;hikes in fees&nbsp;without corresponding enhancements in service quality.
Visa and Mastercard have maintained a stronghold on the payment card market, prompting U.K. lawmakers to call for more stringent oversight by the PSR, which initiated this investigation, reported Reuters.&nbsp;
Over the past five years, and after adjusting for volume changes, Mastercard and Visa have raised their scheme and processing fees by over 30% in real terms.&nbsp;
However, as per the&nbsp;regulatory, there is scant evidence to suggest that service quality has improved in tandem with these fee increases.
The&nbsp;PSR&#8217;s&nbsp;interim report, spanning 158 pages, estimates that these fee hikes have added over £250 million to the costs&nbsp;faced by&nbsp;U.K. businesses.&nbsp;
&#8220;Every time someone uses a Mastercard or Visa card, UK businesses have to pay fees. These fees have significantly increased over recent years, and those increases cannot be explained by improvement in service quality,&#8221;&nbsp;said Chris Hemsley, Managing Director of the PSR.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38795410/visa-mastercard-have-255t-opportunity-analyst-says-generative-ai-could-drive-upside" rel="noreferrer noopener">Visa, Mastercard Have $255T Opportunity, Analyst Says: Generative AI&nbsp;&#8216;Could Drive Upside To Fundamentals&#8217;</a>
Given that Mastercard and Visa cards account for 95% of transactions using U.K.-issued cards, businesses have little alternative but to absorb these increased costs.
The PSR has suggested several remedies for public consultation, including improved transparency for users and obligations on Mastercard and Visa to explain, consult on, and document the reasons behind price changes.&nbsp;
&#8220;The remedies would also increase transparency around Mastercard and&nbsp;Visa's&nbsp;UK operations, allowing the PSR to better hold them to account,&#8221;&nbsp;as per the regulatory statement.
The public consultation will remain open until July 30, with a&nbsp;final report on card schemes and processing fees expected in the last quarter of the year.&nbsp;
Should the final report confirm that the market is not functioning effectively, the PSR will consult on implementing any necessary remedies.
Read Next:&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/05/38708367/mastercards-new-tech-could-change-how-banks-handle-money-and-securities" rel="noreferrer noopener">Mastercard&#8217;s&nbsp;New Tech Could Change How Banks Handle Money and Securities</a>
Price Action: MA shares closed lower by 0.13% at $459.66 on Monday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo by In Green via Shutterstock

Equities

Regulations

Media

Visa And Mastercard Under Scrutiny For Fee Increases In The UK - What's On The Cards?

Tonmya is a potential new first-line, centrally acting non-opioid analgesic for the management of fibromyalgia, supported by statistically significant results from two Phase 3 trials &nbsp;
Primary physician research found high level of interest in Tonmya as a potential new treatment option for fibromyalgia
Significant dissatisfaction reported with drugs currently approved by FDA for the treatment of fibromyalgia
Analysis of claims data revealed that addictive opioids are prescribed more frequently than currently approved drugs following fibromyalgia diagnosis
New Drug Application (NDA) submission to the FDA on track for the second half of 2024
CHATHAM, N.J., May 21, 2024 (GLOBE NEWSWIRE) -- &nbsp;<a href="https://www.globenewswire.com/Tracker?data=6Eqe4vSfDtEt5jSvS6M2G9qx0xUTJlR7A1HlbCs9bV4ilmT58FgE9rTRVIorDiJ_gylpUnw6KMScRJoC0-NiByhdrjXeTCN1JOo4DwuXzPNCJ3HcaX_4gJApYrZfMPPA">Tonix Pharmaceuticals Holding Corp.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that <a href="https://www.globenewswire.com/Tracker?data=ZGgBvvZ4YCO0wA5yop-Mp14yONOITnyQuOCEeCbNlV9gZ8Y4lNQG8LKuofwLi2KokByM_J2tixEr3yHW0MhctD1LHh0r-dO9pWDUghpHUkpCaM7s72u4x_RNa0ig5vxX">EVERSANA&#xAE; Life Science Services, LLC,</a> a leading provider of commercialization services to the global life sciences industry, completed the initial phase of an assessment of the U.S market opportunity for TonmyaTM (also known as TNX-102 SL, cyclobenzaprine HCl sublingual tablets), a potential new first line therapy for the management of fibromyalgia. Tonix previously announced that EVERSANA was selected to support the launch strategy and commercial planning of Tonmya. Specifically, EVERSANA is working with Tonix to assess the fibromyalgia landscape and help plan an efficient go-to-market (GTM) strategy.

TNXP

Tonix Pharmaceuticals Reports Key Findings From Initial Phase Of EVERSANA Market Opportunity Analysis For Tonmya For The Management Of Fibromyalgia

Eagle Point Credit Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECC#NYSE">ECC</a>) reported quarterly earnings of $0.31 per share which missed the analyst consensus estimate of $0.34 by 8.82 percent. This is a 3.13 percent decrease over earnings of $0.32 per share from the same period last year. The company reported quarterly sales of $40.810 million which missed the analyst consensus estimate of $41.452 million by 1.55 percent. This is a 27.86 percent increase over sales of $31.918 million the same period last year.

Earnings Misses

Eagle Point Credit Co Q1 2024 Adj EPS $0.31 Misses $0.34 Estimate, Sales $40.810M Miss $41.452M Estimate

Onfolio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONFO#NASDAQ">ONFO</a>) reported quarterly losses of $(0.14) per share. This is a 46.15 percent increase over losses of $(0.26) per share from the same period last year. The company reported $1.59 million in sales this quarter. This is a 17.33 percent increase over sales of $1.35 million the same period last year.

ONFO

Onfolio Holdings Q1 EPS $(0.14) Up From $(0.26) YoY, Sales $1.59M Up From $1.35M YoY

One person has died following a Singapore Airlines (SIA) flight from London to Singapore that encountered severe turbulence on Tuesday.
What Happened: The flight, SQ321, took off from London&#8217;s Heathrow Airport at 10:38 p.m. local time on Monday and was diverted to Bangkok on Tuesday. It landed at Suvarnabhumi Airport at 3:45 p.m. local time (4:45 p.m. Singapore time), <a href="https://www.channelnewsasia.com/singapore/sia-singapore-airlines-death-turbulence-london-bangkok-4352051">reported</a> Channel News Asia.
SIA confirmed the fatality and injuries on board the Boeing 777-300ER. The airline is working with Thai authorities to provide medical assistance and is sending a team to Bangkok to offer further support. The deceased&#8217;s nationality and whether the person was a passenger or crew member has not been disclosed yet.
&#8220;We can confirm that there are injuries and one fatality on board the Boeing 777-300ER. There were 211 passengers and 18 crew on board,&#8221; said SIA.
See Also: <a href="https://www.benzinga.com/news/24/05/38908073/trump-vs-biden-poll-reveals-surprise-preference-for-one-candidate-over-other-when-it-comes-to-econom?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump Vs Biden: Poll Reveals Surprise Preference For One Candidate Over Other When It Comes To Economy</a>
SIA has also advised those at Changi Airport to assist SQ321 passengers to proceed to any information counter for help. Singapore&#8217;s Minister for Transport, Chee Hong Tat, expressed condolences to the deceased&#8217;s family.
Why It Matters: This incident comes when Boeing has been under<a href="https://www.benzinga.com/news/24/03/37580235/boeing-faces-enormous-scrutiny-after-recent-mishaps-report"> intense scrutiny for safety issues</a>. The company has faced a series of mishaps, including a fuselage blowout on an Alaska Air Group Inc. flight in January 2024, leading to a criminal investigation by the Justice Department. This has prompted U.S. Transportation Secretary Pete Buttigieg to emphasize the need for rigorous assessments of Boeing to ensure airline safety.
Boeing&#8217;s production of 737 MAX jetliners has also been significantly affected by<a href="https://www.benzinga.com/markets/equities/24/04/38093903/boeing-faces-production-slowdown-amid-regulatory-scrutiny-prompts-industry-ripples-and-investor-"> increased factory inspections </a>and a slowdown on the assembly line near Seattle, following the blowout incident. The FAA has implemented a production limit of 38 jets per month, but the monthly production rate has been fluctuating well below this level.
These safety concerns have led to a Senate subcommittee&#8217;s decision to investigate fresh safety allegations regarding Boeing&#8217;s 787 Dreamliner. The FAA is looking into<a href="https://www.benzinga.com/markets/equities/24/04/38175874/boeing-787-dreamliner-safety-claims-to-get-senate-grilling-after-engineers-warning"> claims by a whistleblower</a> and engineer that the Dreamliner could potentially disintegrate due to improperly assembled parts of the plane&#8217;s main body.
Read Next: <a href="https://www.benzinga.com/news/24/05/38909985/this-important-evidence-could-determine-donald-trumps-fate-in-his-hush-money-trial?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">This Important Evidence Could Determine Donald Trump&#8217;s Fate In His Hush-Money Trial</a>
Image Via Shutterstock
This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors

Global

Severe Turbulence On Singapore Airlines Flight From London To Singapore Leaves One Dead, Several Injured

New Construction to Begin in Q2 2024, Expands Bitcoin Mining Capacity
Soluna Holdings, Inc. ("Soluna" or the "Company"), (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNH#NASDAQ">SLNH</a>), a developer of green data centers for intensive computing applications including Bitcoin mining and AI, announced today financing from <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.springlanecapital.com.&amp;esheet=54005494&amp;newsitemid=20240521033134&amp;lan=en-US&amp;anchor=Spring+Lane+Capital&amp;index=1&amp;md5=65b33774ee879b315c1661708a1d2c42">Spring Lane Capital</a> ("SLC") for a 48 MW expansion of Soluna's flagship behind-the-meter data center, Project Dorothy, ("Dorothy 2") facility. SLC, a private equity firm providing hybrid project capital for sustainability solutions, has agreed to lead the financing round with a commitment of up to $30 million. SLC is also an investor in Project Dorothy 1 and supports Soluna's efforts to accelerate the convergence of renewable energy and high-performance computing.

Financing

SLNH

Soluna Secures $30M From Spring Lane Capital To Fuel Project Dorothy 2; New Construction To Begin In Q2 2024, Expands Bitcoin Mining Capacity

FINRA Announces Approval for Corporate Name Change From "China Infrastructure Construction Corp." to "Cannabis Bioscience International Holdings" And Ticker Symbol Change from "CHNC" to "CBIH".

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Latest News for Cannabis Bioscience Stock (OTC:CBIH)

Monday, April 15, 2024

Friday, December 15, 2023